KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis. PMID 40223516 · Ann Clin Transl Neurol · 2025-Jun 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Do differences in secondary treatment explain mortality impact of prostate cancer screening? - A randomized screening trial. PMID 40221389 · Urol Oncol · 2025-Jun The record describes a secondary analysis of treatment patterns within a randomized screening trial (ERSPC/FinRSPC). While oncology, human, randomized, and includes a time-to-event analysis, it does not meet eligibility because: 1) The intervention is screening, not a drug intervention; 2) The analysis is a secondary/explanatory evaluation of treatment frequencies, not a primary efficacy endpoint; 3) The phase is not clearly Phase III/IIIb or Phase II/III for a drug intervention; 4) The report type is secondary (subgroup/explanatory). Therefore, is_eligible is false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis. PMID 40200006 · Bone Marrow Transplant · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Plant-based diet and oxidative stress-induced DNA damage in post-surgery colorectal cancer patients: Results from a randomized controlled trial. PMID 40180023 · Free Radic Biol Med · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Emulating an existing trial of treatments for prostate cancer using real-world data: challenges and lessons learned. PMID 40147703 · J Clin Epidemiol · 2025-Jun This is a real-world data emulation study of the PR07 trial, not an original report of a randomized controlled trial. While the referenced PR07 trial is likely Phase III, the record itself is a secondary analysis/methodological study, not an original trial report. Additionally, the intervention is radiotherapy added to hormone therapy vs hormone therapy alone; while hormone therapy is a drug, the primary intervention comparison is not drug-based (radiotherapy is non-drug).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer. PMID 40140172 · Breast Cancer Res Treat · 2025-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial. PMID 40138604 · J Clin Oncol · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial. PMID 40128603 · Bone Marrow Transplant · 2025-Jun The record fails to meet key eligibility criteria: it is a non-randomized, pilot/feasibility study (not Phase III/IIIb or Phase II/III), and its primary endpoint is not a time-to-event efficacy outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome. PMID 40120806 · J Allergy Clin Immunol Pract · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. PMID 40098231 · Pediatr Blood Cancer · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial. PMID 40097073 · Radiother Oncol · 2025-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
The effect of vitamin D supplementation on cancer incidence in the randomised controlled D-Health Trial: Implications for policy and practice. PMID 40096917 · J Steroid Biochem Mol Biol · 2025-Jun The record describes a randomized, human oncology trial with a time-to-event endpoint (cancer incidence) and reports primary results. However, it is ineligible because the intervention is not a drug (it is a dietary supplement). The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, but this exclusion is primary.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: Exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial. PMID 40086561 · Photodiagnosis Photodyn Ther · 2025-Jun This is a single-arm, Phase III trial evaluating a diagnostic procedure (photodynamic diagnosis) using a drug (5-ALA) as an imaging agent for bladder cancer detection, not as a therapeutic intervention. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial. PMID 40080805 · J Urol · 2025-Jun 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Stereotactic Body Radiation Therapy vs Radiofrequency Ablation for the Treatment of Small Renal Masses: A Feasibility Study (RADSTER). PMID 40058468 · Urology · 2025-Jun The record describes a randomized feasibility trial of local therapies (SBRT vs RFA) for renal masses. It is oncology, human, and randomized with original results, but lacks a drug intervention, is not Phase III, and reports no primary or secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial. PMID 40053891 · J Clin Oncol · 2025-Jun Eligible Phase III-level randomized trial of maintenance chemotherapy in high-risk rhabdomyosarcoma with primary time-to-event efficacy results (OS, DFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial. PMID 40049332 · Lab Invest · 2025-Jun The report is from a relevant Phase III oncology trial with a drug intervention but does not present a time-to-event efficacy endpoint. It is a secondary analysis focused on clinicopathological characterization of a tumor variant.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial. PMID 40016616 · Ann Surg Oncol · 2025-Jun This record is an economic evaluation of a surgical procedure, not a drug intervention trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elastance May Determine the Neuromuscular Blockade Effect on Mortality in Acute Respiratory Distress Syndrome. PMID 39998496 · Am J Respir Crit Care Med · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the VaLRIETEs study and the SOME-RIETE trial. PMID 39971173 · Am Heart J · 2025-Jun The record is a protocol for an ongoing randomized trial comparing screening strategies, not a report of trial results. It lacks a drug intervention, does not report a time-to-event efficacy endpoint with survival analysis (Kaplan-Meier or HR), and does not provide final or interim efficacy data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Why Women Appear to Have Better Outcomes When Undergoing Screening for Lung Cancer. PMID 39965131 · Ann Am Thorac Soc · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Efficacy and Safety of Continuous Veno-Venous Hemodiafiltration With High Cutoff Membrane Versus High Flux Membrane in Septic Acute Kidney Injury: A Randomized Controlled Study. PMID 39895488 · Artif Organs · 2025-Jun The study is a randomized controlled trial in septic acute kidney injury patients, not an oncology study. It evaluates a medical device/membrane (HCO vs HF) for continuous renal replacement therapy, not a drug intervention. The primary outcomes are cytokine reduction rates and mortality, with no time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. PMID 39890560 · Clin Breast Cancer · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Pilot Trial of Tongue Reconstruction Using the Chimeric Innervated Vastus Lateralis Muscle and Antero-Lateral Thigh Free Flap. PMID 39876833 · Head Neck · 2025-Jun This is a prospective, non-randomized controlled pilot study (not a randomized Phase III trial) evaluating a surgical reconstruction technique. The primary endpoints are complications and functional outcomes (e.g., swallowing, speech), not time-to-event efficacy endpoints like OS, PFS, or DFS. There is no drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. PMID 39846397 · J Eur Acad Dermatol Venereol · 2025-Jun The study fails the oncology requirement (alopecia areata is not a malignant neoplasm), lacks randomization, and does not have a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). PMID 39779412 · Clin Colorectal Cancer · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials. PMID 39755138 · Fertil Steril · 2025-Jun The study investigates uterine fibroids (benign condition) and heavy menstrual bleeding, not a human malignant neoplasm. While it is a randomized Phase III trial with a drug intervention and a time-to-event endpoint, it is excluded because it is not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia. PMID 39732538 · Clin Lymphoma Myeloma Leuk · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. PMID 39665917 · Eur Urol Oncol · 2025-Jun The record is a secondary biomarker analysis of a Phase 3 randomized trial. It meets the criteria for oncology, human, randomized, phase 3, and time-to-event, but it is excluded because it is not a primary report of a drug-containing intervention. The intervention in the original trial was a drug, but this specific report is a biomarker analysis without reporting on the drug intervention itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial. PMID 39657078 · JCO Oncol Pract · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam. PMID 39603883 · Eur Urol Oncol · 2025-Jun Study is a randomized analysis of risk stratification from a screening trial, not a randomized trial of a drug-containing intervention for cancer treatment. It evaluates risk classification systems, not a drug therapy, and does not meet the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial. PMID 39537438 · Eur Urol · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Endoscopic background mucosal resurfacing to prevent metachronous recurrence of superficial esophageal squamous cell cancer after curative endoscopic submucosal dissection: randomized pilot study with 5-year follow-up (with video). PMID 39521094 · Gastrointest Endosc · 2025-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial. PMID 39009705 · Prostate Cancer Prostatic Dis · 2025-Jun The study is a randomized trial in oncology patients, but it examines an exercise intervention (non-drug) and reports cardiometabolic biomarker outcomes, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It lacks a drug-containing intervention and a primary/key secondary time-to-event endpoint, which are required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial. PMID 40739403 · Support Care Cancer · 2025-Jul-31 The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, the primary endpoint is cancer-associated fatigue measured by symptom scales at fixed time points, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the key requirement for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term prognosis of intracorporeal versus extracorporeal anastomosis in stage II/III colorectal cancer (INEX study): study protocol for a multicenter randomized controlled trial in Japan. PMID 40739197 · BMC Cancer · 2025-Jul-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial. PMID 40738506 · BMJ Open Gastroenterol · 2025-Jul-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors and Caregivers in Laos (Project SurvLaos): Protocol for a Pilot Randomized Controlled Trial. PMID 40736921 · JMIR Res Protoc · 2025-Jul-30 This is a protocol for a pilot randomized controlled trial evaluating a mobile health smoking cessation program for cancer survivors and caregivers. It is not a Phase III drug trial, does not have a time-to-event efficacy endpoint, and lacks completed results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life following ileostomy takedown: single-centre, retrospective clinical trial-does closure time matter? PMID 40736758 · Tech Coloproctol · 2025-Jul-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial. PMID 40713037 · BMJ Open · 2025-Jul-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Patient-directed behavioral-physical interventions to alleviate acute hiccups associated with chemotherapy: a prospective randomized controlled trial. PMID 40711569 · Support Care Cancer · 2025-Jul-25 The study is a randomized trial in oncology patients, but it fails eligibility because: 1) the intervention is non-pharmacological (behavioral-physical), not a drug-containing intervention, 2) the primary endpoint is not a time-to-event efficacy endpoint relevant to oncologic treatment (like OS/PFS), and 3) it is not established as a Phase III or definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 40580811 · Eur J Cancer · 2025-Jul-25 The record describes a prospective cohort study (a prespecified study within a phase III trial) assessing genomic profiling agreement between primary tumors and lymph node metastases. It does not report primary efficacy results (e.g., OS, PFS, DFS) or any time-to-event endpoint from the randomized trial. It is an ancillary/translational study, not the original formal result report of a randomized trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. PMID 40513287 · Eur J Cancer · 2025-Jul-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
REPAIR_GETUG P16 relapse in previously irradiated prostate bed: a phase I/II study of stereotactic ablative reirradiation potentiated by a metformine study protocol. PMID 40707156 · BMJ Open · 2025-Jul-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines. PMID 40707153 · BMJ Open · 2025-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial. PMID 40702551 · J Transl Med · 2025-Jul-23 The record describes a randomized, multicenter trial with a drug-containing intervention and primary time-to-event endpoints (OS, PFS), but the abstract and metadata do not explicitly state the trial phase. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. PMID 40696453 · Mol Cancer · 2025-Jul-22 Study meets most criteria but randomization status is not explicitly confirmed in the provided metadata; therefore, eligibility cannot be definitively determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. PMID 40266025 · Blood Adv · 2025-Jul-22 The record is a pooled analysis of four randomized controlled trials (RESONATE, RESONATE-2, iLLUMINATE, HELIOS), but the specific trials are not individually described with sufficient detail (e.g., phase, primary endpoint, drug intervention for the trial itself). The analysis focuses on the association of statin use with outcomes, which is a secondary analysis, not the original primary efficacy report of a trial. Additionally, while statin use is analyzed, the primary drug intervention in the trials is ibrutinib, but the report itself is not a primary trial result report; it is a post-hoc/pooled analysis of existing trial data. The phase of the trials is not explicitly stated in the metadata as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. PMID 40448574 · J Clin Oncol · 2025-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. PMID 40682106 · BMC Med · 2025-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -